January 14, 2013
A Pennsylvania federal judge on Monday signed off on a $21.5 million settlement between GlaxoSmithKline PLC and employee benefit plans in a class action alleging the pharmaceuticals giant filed sham patent suits to intentionally delay generic competition to its antidepressant Wellbutrin SR.
October 27, 2010
GlaxoSmithKline PLC has lost its bid for a judge to revisit a ruling keeping in place claims brought by employee benefit plans over GSK's alleged filing of baseless patent suits to delay generic competition with Wellbutrin SR.
September 15, 2010
GlaxoSmithKline PLC has won a bid to purge all claims related to one patent in a putative class action brought by employee benefit plans that accuses the drugmaker of filing baseless infringement suits in an effort to delay generic competition for the antidepressant Wellbutrin SR.
September 09, 2010
A federal judge has nixed some state claims and allowed others to stand in an indirect purchaser action accusing GlaxoSmithKline PLC of filing baseless patent suits to delay generic competition over Wellbutrin SR, issuing his opinion after considering each individual claim in the context of applicable state law.
March 10, 2010
GlaxoSmithKline PLC has asked a judge to dismiss claims brought by employee benefit plans over the alleged filing of baseless patent suits to delay generic competition with Wellbutrin SR, arguing that the plans cannot proceed under the laws of their home states.
November 03, 2009
A federal judge has purged state antitrust and consumer protection claims from a putative class action brought by employee benefit plans accusing GlaxoSmithKline PLC of filing baseless patent suits to delay generic versions of antidepressant Wellbutrin SR.